Uncategorized
VIDEO: Luminate meets primary, secondary endpoints in phase 2b trial
CHICAGO — At the Ophthalmology Innovation Summit here, Vicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, discusses the results of the phase 2b DEL MAR clinical trial of Luminate for treating diabetic macular edema. In the controlled, double-masked, multicenter, dose-ranging study, Luminate (ALG-1001) met both its primary endpoint for visual acuity and secondary endpoint for reduction in central macular thickness as measured by OCT.